HTR2C and major depressive disorder: Representative drugs include Fluoxetine, Paroxetine, and Citalopram.405–409 Fluoxetine, a weak antagonist of 5-HT2C and 5-HT2A receptors, was approved for marketing in 1988 to treat major depressive disorder.